Kyverna Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Kyverna Therapeutics, Inc. (KYTX) reported Increase Decrease In Operating Lease Liability of -$1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-11
- Kyverna Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$733.00K.
- Kyverna Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$503.00K.
- Kyverna Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$844.00K.
- Kyverna Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$774.00K.
- Kyverna Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$3.34M.
- Kyverna Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$2.40M.
- Kyverna Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.68M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$733.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.24M 10-Q · filed 2026-08-11 | -$2.08M derived: sum of 3 quarters · filed 2026-08-11 | -$2.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$503.00K 10-Q · filed 2026-05-12 | -$1.35M derived: sum of 2 quarters · filed 2026-05-12 | -$2.12M derived: sum of 3 quarters · filed 2026-05-12 | -$2.88M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$844.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.62M derived: sum of 2 quarters · filed 2026-03-26 | -$2.38M derived: sum of 3 quarters · filed 2026-08-11 | -$3.34M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$774.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.53M derived: sum of 2 quarters · filed 2026-08-11 | -$2.50M 10-Q · filed 2025-11-12 | -$3.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$758.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.72M 10-Q · filed 2026-08-11 | -$2.37M derived: sum of 3 quarters · filed 2026-08-11 | -$2.99M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$963.00K 10-Q · filed 2026-05-12 | -$1.61M derived: sum of 2 quarters · filed 2026-05-12 | -$2.23M derived: sum of 3 quarters · filed 2026-05-12 | -$2.84M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$647.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.27M derived: sum of 2 quarters · filed 2026-03-26 | -$1.88M derived: sum of 3 quarters · filed 2026-03-26 | -$2.40M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$621.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.23M derived: sum of 2 quarters · filed 2025-11-12 | -$1.75M 10-Q · filed 2025-11-12 | -$2.21M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$611.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$1.13M 10-Q · filed 2025-08-12 | -$1.59M derived: sum of 3 quarters · filed 2025-08-12 | -$2.04M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$520.00K 10-Q · filed 2025-05-13 | -$983.00K derived: sum of 2 quarters · filed 2025-05-13 | -$1.42M derived: sum of 3 quarters · filed 2025-05-13 | -$1.86M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$904.00K derived: sum of 2 quarters · filed 2025-03-27 | -$1.34M derived: sum of 3 quarters · filed 2025-03-27 | -$1.68M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$441.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$875.00K derived: sum of 2 quarters · filed 2024-11-13 | -$1.22M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$434.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$775.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$341.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |